Mesalazine for the treatment of inflammatory bowel disease

Abstract

Introduction: Ulcerative colitis (UC) and Crohn's disease (CD) represent a chronic inflammatory condition of the bowel that often require lifelong medical therapy for the induction and maintenance of the remission. Mesalazine therapies are available both as oral delayed-release and sustained-release formulation, topical formulations and as prodrug.

Areas covered: Available literature regarding mesalazine is extensively reviewed in this article, covering its mechanism of action, pharmaceutics and pharmacokinetics, clinical efficacy, safety and tolerability in different settings.

Expert opinion: Mesalazine has a well-established role in the management of UC. It is the treatment of choice in active and inactive mild-to-moderate UC combining oral and topical drug. No clear role of mesalazine in prevention of colon cancer has been demonstrated because of the contradictory results coming from case–control and prospective studies. The role of mesalazine in the management of CD is less clear; some studies suggest a potential efficacy of 5-ASA in preventing relapse of CD after surgical resection but more convincing results are needed.

Keywords::

• Crohn's disease
• mesalazine
• therapy
• ulcerative colitis

Declaration of interest

Valeria Criscuoli received a grant from MSD and consulting from Giuliani. Mario Cottone has nothing to declare. Irene Modesto received a consulting grant from MSD. Ambrogio Orlando received a grant from Sofar and Chiesi and a grant for MSD and AbbVie.